• In May 2026, Teva Pharmaceutical Industries Limited presented at the Bank of America Global Healthcare Conference in Las Vegas and at BioMed Israel in Tel Aviv, highlighting its central nervous system portfolio and research progress through senior executives Eric A. Hughes and Eran Harary.
• These appearances came shortly after Teva reported that sales from its central nervous system medicines, including Ajovy, Uzedy, and Austedo, rose very large year-on-year to US$837 million in the first quarter, underscoring growing investor attention on its branded portfolio and recent Emalex acquisition.
• With this backdrop of very large CNS portfolio growth and the Emalex acquisition, we’ll now examine how these developments influence Teva’s investment narrative.

Uncover the next big thing with 28 elite penny stocks that balance risk and reward.

Teva Pharmaceutical Industries Investment Narrative Recap

To own Teva today, you need to believe its shift toward higher margin central nervous system drugs can offset slow growth and pricing pressure in generics, while the company continues to manage its sizeable debt. The sharp year on year rise in CNS sales and visibility at major conferences supports that branded pivot, but the biggest near term swing factor remains execution on this concentrated portfolio, with pricing and reimbursement pressure on AUSTEDO still a key risk.

The recent 42.1 percent year on year jump to US$837 million in CNS sales, helped by Ajovy, Uzedy and Austedo, is the clearest link to this story. It highlights how much of Teva’s near term narrative now rests on a handful of branded assets and the Emalex acquisition, at the same time as the company is working to improve margins and service more than US$15 billion of net debt.

Yet even with strong CNS growth, investors should be aware that pricing and reimbursement pressure on AUSTEDO could...

Teva Pharmaceutical Industries' narrative projects $18.1 billion revenue and $2.3 billion earnings by 2029. This requires 1.4% yearly revenue growth and about a $0.7 billion earnings increase from $1.6 billion today.

Uncover how Teva Pharmaceutical Industries' forecasts yield a $40.09 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming only about 1 percent annual revenue growth and US$1.6 billion of earnings by 2028, showing how differently you might weigh pipeline execution risk versus today’s CNS momentum, and why it is worth comparing several viewpoints before deciding what this latest news might mean.

Explore 5 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth as much as 60% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Teva Pharmaceutical Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teva Pharmaceutical Industries' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Find 47 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.